Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy. METHODS: In this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) as compared with FOLFOX4 alone, according to RAS (KRAS or NRAS) or BRAF mutation status. A total of 639 patients who had metastatic colorectal cancer without KRAS mutations in exon 2 had results for at least one of the following: KRAS exon 3 or 4; NRAS exon 2, 3, or 4; or BRAF exon 15. The overall rate of ascertainment of RAS status was 90%. RESULTS: Among 512 patients without RAS mutations, progression-free survival was 10.1 months with panitumumab-FOLFOX4 versus 7.9 months with FOLFOX4 alone (hazard ratio for progression or death with combination therapy, 0.72; 95% confidence interval [CI], 0.58 to 0.90; P=0.004). Overall survival was 26.0 months in the panitumumab-FOLFOX4 group versus 20.2 months in the FOLFOX4-alone group (hazard ratio for death, 0.78; 95% CI, 0.62 to 0.99; P=0.04). A total of 108 patients (17%) with nonmutated KRAS exon 2 had other RAS mutations. These mutations were associated with inferior progression-free survival and overall survival with panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2. BRAF mutations were a negative prognostic factor. No new safety signals were identified. CONCLUSIONS: Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4. In patients who had metastatic colorectal cancer without RAS mutations, improvements in overall survival were observed with panitumumab-FOLFOX4 therapy. (Funded by Amgen and others; PRIME ClinicalTrials.gov number, NCT00364013.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consistent with BRAFV600E mutation, signaling independent of upstream input, anti-EGFR therapy is not useful in patients with BRAFV600E tumors as single agents [93] or in combination with chemotherapy [94].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [94]
In the citing paper
“Additional rare mutations of KRAS, as well as mutations of NRAS, have been associated with primary resistance to treatment.”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [35]
In the citing paper
“Further analysis of molecular subgroups in this study showed that adding panitumumab significantly improved mPFS and mOS in the non-mutated KRAS group but was ineffective in patients with KRAS non-exon 2 mutations [15].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [15]
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
In the citing paper
“The most frequently detected mutations in codons 12 and 13—namely G12V (incidence: 20–25%), G12S (5–7%), G12R (3–5%), G12A (3–5%), and G13D (15–20%)—are also clinically relevant, with their prevalence varying by tumor type [16,17,18].”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [18]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 5×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
InfluentialSelf-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 4×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
InfluentialSelf-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 3×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“Not serious 48 (19) 28 (11) 76 (15) 50 (19) 24 (9) 74 (14)”
Self-citationVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citationDouillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809 · cited 2×
“Not determined 4/320 (1) 8/321 (2) 12/641 (2)”
Self-citationWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Self-citationRas oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 3×
“Worst grade of 5 14 (5) 16 (6) 30 (6) 19 (7) 10 (4) 29 (5)”
Peeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Self-citation
Research works printed but not linked: 2
- Wojcik P, 2008, Pol J Pathol, 59, 93
- Yuen ST, 2002, Cancer Res, 62, 6451
Cited by
Items 701–800 of 1,008
Voutsadakis, I. A. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103987 · Cited by 32
Lu, X., Li, Y., Li, Y., Zhang, X., Shi, J., Feng, H., Yu, Z., & Gao, Y. (2023) · BMC Cancer · doi:10.1186/s12885-023-11600-z · Cited by 33
“RAS mutations have been demonstrated to be negative predictive biomarkers of anti-EGFR mAb response and survival benefit [10, 11].”
BackgroundExtended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers.
Al-Shamsi, H. O., Alhazzani, W. A., & Wolff, R. A. (2015) · PubMed Central · doi:10.3978/j.issn.2078-6891.2015.016 · Cited by 34
“initiated the concept of Extended RAS analysis (39).”
BackgroundMethodResultInfluentialThe pharmacogenomics of drug resistance to protein kinase inhibitors
Gillis, N., & McLeod, H. L. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.008 · Cited by 33
“…analysis of 1,183 patients who received either FOLFOX-panitumumab or FOLFOX alone revealed that mutation status in both KRAS and NRAS were predictive of response to panitumumab (HR for progression or death in RAS wild type 0.72, 95% CI 0.58–0.99, p= 0.0004) (Douillard et al., 2013).”
BackgroundInfluentialKienle, D., Dietrich, D., Ribi, K., WICKI, A. N., Quagliata, L., Winterhalder, R. C., Koeberle, D., Horber, D., Bastian, S., Kueng, M., et al. (2018) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2018.11.011 · Cited by 31
Au, T. H., Wang, K., Stenehjem, D. D., & Garrido‐Laguna, I. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.04 · Cited by 32
“In addition, cetuximab and panitumumab have been shown to be suboptimal therapies in NRASmutated CRC (66).”
BackgroundNisa, L., Häfliger, P., Turan, M. P., Giger, R., Francica, P., Aebersold, D. M., Charles, R., Zimmer, Y., & Medová, M. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0660-5 · Cited by 30
“The clearest example, as mentioned above, is the predictive value of pre-therapeutic screening of KRAS mutations in patients with colorectal cancer prior to cetuximab therapy, an approach allowing individuallytailored therapeutic strategies [10, 11].”
Santos, C. G., Azuara, D., Viéitez, J. M., Páez, D., Falcó, E., Élez, E., López, C., Valladares, M., Robles-Díaz, L., Alfonso, P. G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz082 · Cited by 35
“Mutated KRAS exon 2 was initially claimed responsible for panitumumab resistance [4], but subsequent analyses revealed the detrimental effect of other KRAS (exons 3/4) and NRAS (exons 2/3/4) mutations [5].”
BackgroundMethodMolecular Insights Into Colorectal Carcinoma
Requena, D. O., & Garcia-Buitrago, M. T. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.09.014 · Cited by 33
Next-Generation Companion Diagnostics: Promises, Challenges, and Solutions
Khoury, J. D., & Catenacci, D. V. T. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0063-ed · Cited by 28
“Among the advantages envisioned for CACDF status are (1) enhancing patient safety in biomarker-selective clinical trials, (2) reducing variability of testing to determine FDA-approved eligibility for a targeted therapy, and (3) a shorter path to FDA approval for a targeted therapeutic agent evaluated in a CACDF labora…”
BackgroundAugustine, T. A., Baig, M., Sood, A., Budagov, T., Atzmon, G., Mariadason, J. M., Aparo, S., Maitra, R., & Goel, S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.561 · Cited by 27
“Expanding the repertoire of Ras mutations has further narrowed the spectrum with better identification of patients (Douillard et al, 2013), but there still remains ample room for improvement.”
BackgroundDavis, T. B., Yang, M., Schell, M. J., Wang, H., Ma, L., Pledger, W. J., & Yeatman, T. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-27584-x · Cited by 27
Addressing Challenges in Targeted Therapy for Metastatic Colorectal Cancer
Hage, M. E., Su, Z., & Linnebacher, M. (2025) · Cancers · doi:10.3390/cancers17071098 · Cited by 34
Successes and Limitations of Targeted Cancer Therapy in Colon Cancer
Köhne, C. (2014) · Progress in tumor research · doi:10.1159/000356436 · Cited by 27
Helden, E. J. V., van Oordt, C. W. M. D. H., Heymans, M. W., Ket, J. C. F., van den Oord, R., & Verheul, H. M. W. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9668-y · Cited by 34
“Recently, the same was demonstrated for mutations in KRAS exons 3 and 4, and for the rare mutations in neuroblastoma rat sarcoma (NRAS) viral oncogene homolog exon 2–4 [6].”
BackgroundShimada, Y., Kameyama, H., Nagahashi, M., Ichikawa, H., Muneoka, Y., Yagi, R., Tajima, Y., Okamura, T., Nakano, M., Sakata, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20510 · Cited by 30
“Randomized phase III clinical trials have shown a survival benefit of these anti-EGFR monoclonal antibodies in RAS wild-type metastatic CRC [12-14]; however, tumor location has not traditionally been included as a stratification criterion in clinical trials.”
BackgroundShimada, Y., Tajima, Y., Nagahashi, M., Ichikawa, H., Oyanagi, H., Okuda, S., Takabe, K., & Wakai, T. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.06.020 · Cited by 31
Yamada, T., Matsuda, A., Takahashi, G., Iwai, T., Takeda, K., Ueda, K., Kuriyama, S., Koizumi, M., Shinji, S., Yokoyama, Y., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01691-0 · Cited by 36
Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial
Richman, S. D., Adams, R., Quirke, P., Butler, R., Hemmings, G., Chambers, P. A., Roberts, H., James, M. D., Wozniak, S., Bathia, R., et al. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203097 · Cited by 28
Tracking Cellular and Immune Therapies in Cancer
Kurtz, D. M., & Gambhir, S. S. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-411638-2.00008-2 · Cited by 27
Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases
Roussille, P., Tachon, G., Villalva, C., Milin, S., Frouin, É., Godet, J., Berger, A., Emambux, S., Petropoulos, C., Wager, M., et al. (2018) · Cancers · doi:10.3390/cancers10120504 · Cited by 31
“In our study, molecular features of CRC with BM were in accordance with rates observed in all-comers mCRC except for RAS mutations that appear to be higher than rates commonly observed in mCRC [11].”
ResultSemira, C., Wong, H., Field, K. M., Lee, M., Lee, B., Nott, L. M., Shapiro, J. D., Wong, R., Tie, J., Tran, B., et al. (2018) · Internal Medicine Journal · doi:10.1111/imj.14115 · Cited by 30
Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review
Cotan, H. T., Emilescu, R. A., Iaciu, C. I., Orlov-Slavu, C. M., Olaru, M., Popa, A. M., Jinga, M., Niţipir, C., Schreiner, O. D., & Ciobanu, R. C. (2024) · Cancers · doi:10.3390/cancers16233928 · Cited by 35
The safety of monoclonal antibodies for treatment of colorectal cancer
Berger, M. D., & Lenz, H. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1167186 · Cited by 27
“009) in those treated with panitumumab-FOLFOX versus FOLFOX alone.[30] Additionally, patients with the above-mentioned RAS mutations receiving panitumumab and FOLFOX had an inferior PFS and OS compared to those treated with FOLFOX alone.”
ResultOral drugs in the treatment of metastatic colorectal cancer
Kwakman, J. J. M., & Punt, C. J. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1186649 · Cited by 27
“to patients with RAS wildtype tumours [9]), and regorafenib (a multikinase inhibitor).”
BackgroundPharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
Bignucolo, A., Mattia, E. D., Cecchin, E., Roncato, R., & Toffoli, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071522 · Cited by 29
Pang, S.-W., Awi, N. J., Armon, S., Lim, W. W.-D., Low, J. S.-H., Peh, K.-B., Peh, S., & Teow, S. (2019) · Diagnostics · doi:10.3390/diagnostics10010009 · Cited by 29
“Previously, KRAS mutation was identified only by mutations in Codon 12 and 13 of Exon 2, which was subsequently found to be insufficient for an accurate prediction of treatment response [60].”
BackgroundWilliams, C. J. M., Seligmann, J. F., Elliott, F., Shires, M., Richman, S. D., Brown, S., Zhang, L., Singh, S., Pugh, J., Xu, X.-M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0120 · Cited by 27
Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview
García‐Foncillas, J., Argente, J., Bujanda, L., Cardona, V., Casanova, B., Montés, A. F., Horcajadas, J. A., Íñiguez, A., Ortíz, A., Pablos, J. L., et al. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00544-4 · Cited by 27
The HER family as therapeutic targets in colorectal cancer
Ye, P., Wang, Y., Li, R., Chen, W., Wan, L., & Cai, P. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103681 · Cited by 28
Role of EGFR and FASN in breast cancer progression
Chaturvedi, S., Biswas, M., Sadhukhan, S., & Sonawane, A. (2023) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-023-00771-w · Cited by 35
“For instance, RAS induces resistance to lapatinib (a dual EGFR/HER2 inhibitor) (Zoppoli et al. 2010), cetuximab and panitu-mumab (EGFR targeting mAbs) (Douillard et al. 2013).”
BackgroundHeterogeneity in precision oncology
Tomasik, B., Garbicz, F., Braun, M., Bieńkowski, M., & Jassem, J. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.23 · Cited by 31
“In colorectal cancer, cetuximab, which is a chimeric antibody against the epidermal growth factor receptor (EGFR), is effective only against wild-type rat sarcoma (RAS) family oncogenes (Van Cutsem et al., 2009; Douillard et al., 2013).”
BackgroundSelf-citationCombined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
Davis, S. L., Robertson, K. M., Pitts, T. M., Tentler, J. J., Bradshaw‐Pierce, E. L., Klauck, P. J., Bagby, S. M., Hyatt, S. L., Selby, H. M., Spreafico, A., et al. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00120 · Cited by 26
“…with KRAS exon 2 mutations (Amado et al., 2008; Karapetis et al., 2008), and now extended RASmutations (KRAS exon 2, 3, 4, and NRAS exon 2, 3, 4) (Douillard et al., 2013; Heinemann et al., 2014), do not derive benefit from treatment with EFGRtargeting monoclonal antibodies, the treatment…”
BackgroundSoda, H., Maeda, H., Hasegawa, J., Takahashi, T., Hazama, S., Fukunaga, M., Kono, E., Kotaka, M., Sakamoto, J., Nagata, N., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1685-z · Cited by 28
“Recent retrospective studies analyzing samples from prospective clinical trials, most of which were published after the initiation of the present Phase II study, have reported that mutations at NRAS codons 12, 13 and 61 have a negative effect on anti-EGFR antibody therapy in mCRC patients [28, 29].”
BackgroundA new generation of companion diagnostics: cobasBRAF, KRASandEGFRmutation detection tests
Angulo, B., López‐Ríos, F., & de Castro, D. G. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.910120 · Cited by 28
“Given the almost ubiquitous overexpression of EGFR in CRC, monoclonal antibodies against EGFR have been successfully developed and are now approved for the treatment of CRC in the first line.”
BackgroundInfluentialChan, D. L. H., Pavlakis, N., Shapiro, J. D., Price, T. J., Karapetis, C. S., Tebbutt, N. C., & Segelov, E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135599 · Cited by 31
“Of the above trials, four trials—two using oxaliplatin (OPUS, PRIME)[31, 32] and two using irinotecan (CRYSTAL, Study 181)[33] have reported outcomes according to extended RAS status.”
Sasaki, Y., Hamaguchi, T., Yamada, Y., Takahashi, N., Shoji, H., Honma, Y., Iwasa, S., Okita, N. T., Takashima, A., Kato, K., et al. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.2.539 · Cited by 27
“KRAS mutational status is predictive of resistance to anti-EGFR monoclonal antibodies in metastatic CRC (Cutsem et al., 2011; Douillard et al., 2013).”
BackgroundSpectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment
Dienstmann, R., & Tabernero, J. M. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000191 · Cited by 36
“88).(14,15) Three studies, phase III trials FIRE-3 (AIO KRK-0306)(16) and CALGB/SWOG 80405,(17) and phase II trial PEAK,(18) directly compared the addition of bevacizumab versus cetuximab or panitumumab to FOLFOX/FOLFIRI in terms of efficacy outcomes.”
BackgroundSelf-citationYousef, A. I., El-Masry, O. S., & Yassin, E. H. (2016) · Tumor Biology · doi:10.1007/s13277-016-5284-7 · Cited by 26
Drug combinatorics and side effect estimation on the signed human drug-target network
Torres, N. B., & Altafini, C. (2016) · BMC Systems Biology · doi:10.1186/s12918-016-0326-8 · Cited by 31
Osawa, H. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1145 · Cited by 27
“However, the progression‐free survival (PFS) of first‐line chemotherapy in mCRC has not improved over the past decade (5-12).”
Integrative omics analyses broaden treatment targets in human cancer
Sengupta, S., Sun, S. Q., Huang, K., Oh, C., Bailey, M. H., Varghese, R., Wyczalkowski, M. A., Ning, J., Tripathi, P., McMichael, J. F., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0564-z · Cited by 28
“Based on these 19 drug-variant combinations, 4 out of 6 sensitive mutations in DEPO (KRAS G12V, BRAF V600E, NRAS Q61K, and KRAS G12D) were significantly associated with sensitivity to at least one of their paired drugs in both the cancer-type-specific and non-specific settings.”
InfluentialGoel, G. (2018) · Cancer Management and Research · doi:10.2147/cmar.s162967 · Cited by 27
Maurel, J., Alonso, V., Escudero, P., Fernández-Martos, C., Salud, A., Méndez, M., Gallego-Plazas, J., Rodríguez, J. R., Martín-Richard, M., Fernández-Plana, J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00289 · Cited by 28
Arriga, R., Caratelli, S., Lanzilli, G., Ottaviani, A., Cenciarelli, C., Sconocchia, T., Spagnoli, G. C., Iezzi, G., Roselli, M., Lauro, D., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32618 · Cited by 28
“Moreover, although cetuximab can mediate ADCC in vitro,(5) it has no impact on progression of KRAS-mutated colorectal cancers.(3,4) Furthermore, our experiments were performed upon repeated administration of anti-asialo-GM1Abs, resulting in NK cell depletion.”
BackgroundAdenocarcinoma with mixed subtypes is a rare but aggressive histologic subtype in colorectal cancer
Sheng, H., Wei, X., Mao, M., He, J., Luo, T., Lu, S., Zhou, L., Huang, Z. L., & Yang, A. (2019) · BMC Cancer · doi:10.1186/s12885-019-6245-5 · Cited by 26
Cacciola, N. A., Calabrese, C., Malapelle, U., Pellino, G., Stefano, A. D., Sepe, R., Sgariglia, R., Quintavalle, C., Federico, A., Bianco, A., et al. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22322 · Cited by 26
“In this regard, other members of the RAS family may be involved and, recently, the European Medicine Agency has requested to analyze the mutational status of exons 3 and 4 of KRAS and exons 2, 3, and 4 of NRAS, in addition to exon 2 of KRAS [12].”
BackgroundAdaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer
Omolo, B., Yang, M., Lo, F. Y., Schell, M. J., Austin, S., Howard, K., Madan, A., & Yeatman, T. J. (2016) · BMC Medical Genomics · doi:10.1186/s12920-016-0225-2 · Cited by 25
“It has been recently reported that mutations in BRAF and NRAS that also activate the RAS pathway may account for EGFRi therapy resistance in some of the wild-type KRAS CRCs [7, 10, 12, 14].”
BackgroundAref‐Eshghi, E., Abadi, A., Farhadieh, M., Hooshmand, A., Ghasemi, F., Youssefian, L., Vahidnezhad, H., Kerrins, T. M., Zhao, X., Akbarzadeh, M., et al. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01967-0 · Cited by 31
“In contrast, if the metastases are derived from non-small-cell lung cancer (NSCLC), the therapeutic approach would shift toward using tyrosine kinase inhibitors (e.g., osimertinib) for EGFR-mutant cases or immune checkpoint inhibitors like pembroli-zumab for PD-L1-expressing tumors [201, 202].”
Next-generation sequencing and empowering personalised cancer medicine
McDermott, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.008 · Cited by 32
Llovet, P., Sastre, J., Sanz‐Ortega, J., Bando, I., Ferrer, M., Alfonso, P. G., Donnay, O., Carrato, A., Jiménez, A., Aranda, E., et al. (2015) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-015-0165-0 · Cited by 30
“FOLFOX [7, 9, 10] or panitumumab with FOLFOX [6, 8], with patients without RAS mutation exhibiting better”
MethodInfluentialMulticenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer
Prieto‐Potín, I., Montagut, C. O., Bellosillo, B., Evans, M., Smith, M. R., Melchior, L. C., Werner, R., Bennett, M., Pennati, V., Castiglione, F., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.05.008 · Cited by 26
Jacome, A. A. D. A., Vreeland, T. J., Johnson, B., Kawaguchi, Y., Wei, S. H., You, Y. N., Vilar, E., Vauthey, J., & Eng, C. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01169-w · Cited by 27
ten Hoorn, S., Sommeijer, D. W., Elliott, F., Fisher, D. J., de Back, T. R., Trinh, A., Koens, L., Maughan, T., Seligmann, J. F., Seymour, M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01477-9 · Cited by 26
“Anti-EGFR agents (cetuximab, panitumumab) may be given as monotherapy in chemorefractory patients, but are usually combined in earlier lines (first or second line) with chemotherapy, with either an oxaliplatin or irinotecan backbone, which are both considered effective and safe regimens [1, 2].”
BackgroundOhta, R., Yamada, T., Sonoda, H., Matsuda, A., Shinji, S., Takahashi, G., Iwai, T., Takeda, K., Ueda, K., Kuriyama, S., et al. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.07.017 · Cited by 29
Fountzilas, C. K., Bajor, D. L., Mukherjee, S., Saltzman, J. N., Witkiewicz, A. K., Maguire, O., Minderman, H., Nambiar, R., Rosenheck, H. R., Knudsen, E. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1650 · Cited by 27
van de Geest, T. W., van Amerongen, M. J., Nierop, P. M. H., Höppener, D. J., Grünhagen, D. J., Moelker, A. D., Fütterer, J. J., Verhoef, C. K., & de Wilt, J. H. W. (2022) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2022.01.008 · Cited by 30
Meng, L., Thapa, R., Delgado, M., Gómez, M. F. L., Ji, R., Knepper, T. C., Hubbard, J. M., Wang, X., Permuth, J. B., Kim, R. D., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.20035 · Cited by 30
Regorafenib in metastatic colorectal cancer
Bianchi, A. S., Zeppellini, A., Amatu, A., Ricotta, R., Bencardino, K. B., & Siena, S. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.894887 · Cited by 26
“Limitations to the use of anti-EGFR agents have been imposed by the identification of predictive biomarkers and molecular mechanisms responsible for intrinsic resistance, especially the mutations of KRAS gene (exons 2, 3, 4), occurring in 50–53% of CRC patients, NRAS (exons 2, 3, 4) (7–8%) or BRAF (V600E) (8–10%) [9].”
Self-citationJeong, W.-J., Cha, P.-H., & Choi, K.-Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9862 · Cited by 28
Pietrantonio, F., Maggi, C., Bartolomeo, M. D., Facciorusso, M. G., Perrone, F., Testi, M., Iacovelli, R., Miceli, R., Bossi, I. E., Leone, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092147 · Cited by 26
“Recently, a broader mutation testing of RAS gene (at exons 2, 3, or 4 of both KRAS and NRAS) has been validated for treatment personalization in advanced colorectal cancer through the support of several studies [21].”
BackgroundMizukami, T., Togashi, Y., Naruki, S., Banno, E., Terashima, M., Velasco, M. A. D., Sakai, K., Yoneshige, A., Hayashi, H., Fujita, Y., et al. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22476 · Cited by 38
“2 mutations, less common RAS gene mutations including KRAS exons 3 and 4 and NRAS exons 2–4 have been suggested as predictive biomarkers for antiEGFR antibodies [9].”
BackgroundBRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer
Chen, K.-H., Lin, Y., Liau, J., Tsai, J., Tseng, L., Lin, L., Liang, J., Lin, B., Hung, J., Chang, Y., et al. (2016) · Medical Oncology · doi:10.1007/s12032-016-0756-6 · Cited by 28
“Paradoxically, several studies have shown that BRAF mutant CRC patients have poor prognoses [2, 4, 14, 32, 34].”
InfluentialToll-like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer
Maitra, R., Augustine, T. A., Dayan, Y., Chandy, C., Coffey, M. C., & Goel, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16812 · Cited by 27
“It has been universally accepted that the presence of a KRAS mutation is a negative predictive marker of the two USFDA approved anti-EGFR monoclonal antibodies, namely cetuximab and panitumumab [15].”
BackgroundSeligmann, J. F., Hatch, A. J., Richman, S. D., Elliott, F., Jacobs, B., Brown, S., Hurwitz, H., Barrett, J. H., Quirke, P., Nixon, A. B., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3168 · Cited by 25
Turin, I., Delfanti, S., Ferulli, F., Brugnatelli, S., Tanzi, M., Maestri, M., Cobianchi, L., Lisini, D., Luinetti, O., Paulli, M., et al. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000205 · Cited by 31
Ciliberto, D., Staropoli, N., Caglioti, F., Chiellino, S., Ierardi, A., Ingargiola, R., Botta, C., Arbitrio, M., Correale, P., Tassone, P., et al. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.003 · Cited by 28
Froelich, M. F., Heinemann, V., Sommer, W. H., Holch, J. W., Schoeppe, F., Hesse, N., Baumann, A. B., Kunz, W. G., Reiser, M. F., Ricke, J., et al. (2018) · European Radiology · doi:10.1007/s00330-018-5454-7 · Cited by 26
LncRNA, a novel target biomolecule, is involved in the progression of colorectal cancer.
Sun, W., Ren, S., Li, R., Zhang, Q., & Song, H. (2019) · PubMed · Cited by 28
Loupakis, F., Stein, A., Ychou, M., Hermann, F., Salud, A., & Osterlund, P. J. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0400-y · Cited by 28
Rodrigues, D., Longatto‐Filho, A., & Martins, S. F. F. (2016) · BioMed Research International · doi:10.1155/2016/6896024 · Cited by 27
“On the other hand, its utility as a prognostic factor is more consensual [54, 67].”
BackgroundKim, T. W., Elme, A., Park, J. O., Udrea, A. A., Kim, S. Y., Ahn, J. B., Villalobos-Valencia, R., Krishnan, S., Manojlovic, N. S., Guan, X., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.03.008 · Cited by 24
Isnaldi, E., Garuti, A., Cirmena, G., Scabini, S., Rimini, E., Ferrando, L., Lia, M., Murialdo, R., Tixi, L., Carminati, E., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1879-2 · Cited by 26
“These percentages do not differ from those described in previous clinical studies [19].”
ResultHiyoshi, Y., Miyamoto, Y., Kiyozumi, Y., Eto, K., Nagai, Y., Iwatsuki, M., Iwagami, S., Baba, Y., Yoshida, N., & Baba, H. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01523-w · Cited by 25
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer
Strickler, J. H., Rushing, C. N., Uronis, H. E., Morse, M. A., Niedzwiecki, D., Blobe, G. C., Moyer, A. N., Bolch, E. K., Webb, R., Haley, S. T., et al. (2021) · The Oncologist · doi:10.1002/onco.13678 · Cited by 25
Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives
Moati, É., Taly, V., Garinet, S., Didelot, A., Taïeb, J., Laurent‐Puig, P., & Zaanan, A. (2021) · Cancers · doi:10.3390/cancers13194743 · Cited by 26
Molecular testing for colorectal cancer: Clinical applications
Имянитов, Е. Н., & Kuligina, E. S. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i10.1288 · Cited by 33
Zhang, W., Zhang, Z., Lou, S., Li, D., Zhi-jun, M., & Xue, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.929342 · Cited by 25
“RAS mutations are associated with a poor prognosis with EGFR inhibitor therapy (29).”
BackgroundKendzia, S., Franke, S., Kröhler, T., Golob‐Schwarzl, N., Schweiger, C., Toeglhofer, A. M., Skofler, C., Uranitsch, S., Heliebi, A. E., Fuchs, J., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01787-x · Cited by 26
“Nonetheless novel biomarkers are needed, since EGFR treatment with cetuximab is not sufficient in a significant part of wild type tumors [7, 8].”
BackgroundTreatment of metastatic colorectal cancer: focus on panitumumab
Hawkes, E. A., Tay, R. Y., & Wong, R. (2015) · Cancer Management and Research · doi:10.2147/cmar.s71821 · Cited by 29
Lutz, L., Fitzner, I. C., Ahrens, T. D., Geißler, A.-L., Makowiec, F., Hopt, U. T., Bogatyreva, L., Hauschke, D., Werner, M., & Laßmann, S. (2016) · PubMed · Cited by 32
Up-regulation of GTPBP4 in colorectal carcinoma is responsible for tumor metastasis
Yu, H., Jin, S., Zhang, N., & Xu, Q. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.010 · Cited by 24
Bianchi, A. S., Siena, S., Tonini, G., Bardelli, A., & Santini, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.10.006 · Cited by 25
Self-citationFeedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells
Bosch-Vilaró, A., Jacobs, B., Pomella, V., Asbagh, L. A., Kirkland, R. E., Michel, J., Singh, S., Liu, X., Kim, P., Weitsman, G. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13834 · Cited by 26
Nakayama, I., Shinozaki, E., Matsushima, T., Wakatsuki, T., Ogura, M., Ichimura, T., Ozaka, M., Takahari, D., Suenaga, M., Chìn, K., et al. (2017) · BMC Cancer · doi:10.1186/s12885-016-2994-6 · Cited by 24
“KRAS exon 3 and 4/NRAS) in the FIRE-3 and PRIME studies [2, 3], the so called “all RAS mutation” also came to be regarded as a negative biomarker for anti-EGFR antibody treatment [4].”
Weyn, C., Raemdonck, S. V., Dendooven, R., Maes, V., Zwaenepoel, K., Lambin, S., & Pauwels, P. (2017) · BMC Cancer · doi:10.1186/s12885-017-3112-0 · Cited by 26
“NCCN. NCCN Guidelines Version 2.2016 Rectal Cancer.”
BackgroundInfluentialErdem, Z., Schwarz, S., Drev, D., Heinzle, C. F., Réti, A., Heffeter, P., Hudec, X., Holzmann, K., Grasl‐Kraupp, B., Berger, W., et al. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.02.004 · Cited by 26
BRAF-mutant colorectal cancer, a different breed evolving
Lai, E., Pretta, A., Impera, V., Mariani, S., Giampieri, R., Casula, L., Pusceddu, V., Coni, P., Fanni, D., Puzzoni, M., et al. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1470928 · Cited by 27
Udar, N., Lofton–Day, C., Dong, J., Vavrek, D. A., Jung, A. S., Meier, K. M., Iyer, A., Slaughter, R. C., Gutekunst, K. A., Bach, B. A., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2688-3 · Cited by 26
Self-citationPredictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review
Bañobre, J. R., Kandimalla, R., & Goel, A. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00260 · Cited by 29
Wang, B., Wu, S., Huang, F., Shen, M., Jiang, H., Yu, Y., Yu, Q., Yang, Y., Zhao, Y., Zhou, Y., et al. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0142 · Cited by 25
Current Development of Monoclonal Antibodies in Cancer Therapy
Parakh, S., King, D., Gan, H. K., & Scott, A. M. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_1 · Cited by 28
Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes
Avolio, M., & Trusolino, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1531 · Cited by 26
Cho, S.-Y., Han, J. Y., Na, D., Kang, W., Lee, A., Kim, J., Lee, J., Min, S., Kang, J., Chae, J., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0735 · Cited by 24
“However, these anti-EGFR treatments are less effective in patients with KRAS or BRAF mutations (11, 36, 37).”
BackgroundXu, C., Mannucci, A., Esposito, F. M., Oliveres, H., Alonso-Orduña, V., Yubero, A., Fernández-Martos, C., Salud, A., Gallego-Plazas, J., Martín-Richard, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1934 · Cited by 25
Wainberg, Z. A., & Drakaki, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1050375 · Cited by 25
“Clinical trial data evaluating EGFR inhibitors in the first-line setting in patients with mCRC: EGFR inhibitors plus chemotherapy versus chemotherapy alone The CRYSTAL, OPUS, PRIME, COIN and NORDIC VII studies have compared EGFR inhibitors plus standard chemotherapy versus standard chemotherapy alone in the first-line…”
BackgroundMethodInfluentialPanitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
Peeters, M., Karthaus, M., Rivera, F., Terwey, J.-H., & Douillard, J. (2015) · Drugs · doi:10.1007/s40265-015-0386-x · Cited by 24
“randomised in this study; among those 1060 patients, 512 (48 %) were found to have RAS WT mCRC [12].”
InfluentialSelf-citationChibaudel, B., Bonnetain, F., Tournigand, C., de Larauze, M. H., Gramont, A. D. E., Laurent‐Puig, P., Paget, J., Hadengue, A., Notelet, D., Benetkiewicz, M., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1503-7 · Cited by 25
“Moreover, data suggest that only patients with wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS) and wild-type neuroblastoma RAS viral oncogene homolog (NRAS) are likely to benefit from anti-EGFR therapy [10–12].”
Harlé, A., Filhine-Trésarrieu, P., Husson, M., Boidot, R., Rouyer, M., Dubois, C., Leroux, A., & Merlin, J. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0404-7 · Cited by 25
“Other hotspot mutations, KRAS exons 3 and 4 (comprising amino-acids 59–61 and 117–146, respectively) and NRAS exons 2, 3 and 4 (comprising amino-acids 12–13, 59–61 and 117–146, respectively), have been associated with clinical resistance to anti-EGFR mAbs [15].”
BackgroundAdvances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer
Lee, S., & Oh, S. C. (2016) · BioMed Research International · doi:10.1155/2016/7590245 · Cited by 25
Metadata
- Authors
- Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocákova, I., Ruff, P., Błasińska-Morawiec, M., Šmakal, M., Canon, J. L., Rother, M., Williams, R., Rong, A., Wiezorek, J., Sidhu, R., & Patterson, S. D.
- Affiliations
- Institut de Cancérologie de l'Ouest (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-09-12
- Volume
- 369
- Issue
- 11
- Pages
- 1023-1034
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085633477
- Cited by
- 2,263
- References
- 31
- Citations by year
- 2026: 67 · 2025: 98 · 2024: 110 · 2023: 113 · 2022: 125 · 2021: 203 · 2020: 159 · 2019: 178 · 2018: 181 · 2017: 228 · 2016: 251 · 2015: 290 · 2014: 239 · 2013: 16
- FWCI
- 142.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- panitumumab, FOLFOX4, metastatic colorectal cancer, RAS mutations, KRAS exon 2, NRAS, BRAF mutation, anti-EGFR therapy, predictive biomarkers, progression-free survival, overall survival, oxaliplatin, 5-fluorouracil, leucovorin, treatment efficacy and safety, prognostic factors, combination chemotherapy
- MeSH terms
- Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Fluorouracil, Humans, Membrane Proteins, Mutation, Neoplasm Metastasis, Organoplatinum Compounds, Proto-Oncogene Proteins, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.